This review focuses on the mechanisms regulating the synthesis, secretion, biological
actions, and therapeutic relevance of the incretin peptides glucose-dependent insulinotropic …

Glucagon-like peptide 1 (GLP-1) is a 30-amino acid peptide hormone produced in the
intestinal epithelial endocrine L-cells by differential processing of proglucagon, the gene …

The hyperglycemic activity of pancreatic extracts was encountered some 80 yr ago during
efforts to optimize methods for the purification of insulin. The hyperglycemic substance was …

Inhibition of dipeptidyl peptidase 4 (DPP-4) is a novel treatment for type-2 diabetes. DPP-4
inhibition prevents the inactivation of glucagon-like peptide 1 (GLP-1), which increases …

This 24-week, double-blind, randomized, multicenter, placebo-controlled, parallel-group
study performed in 354 drug-naïve patients with type 2 diabetes (T2DM) assessed efficacy …

Abstract Aims/Hypothesis: Vildagliptin is a selective dipeptidyl peptidase IV inhibitor that
augments meal-stimulated levels of biologically active glucagon-like peptide-1. Chronic …

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors represent a new class of oral antihyperglycemic
agents to treat patients with type 2 diabetes. 1 DPP‐4 inhibitors improve fasting and …

Glucagon-like peptide (GLP)-1 mimetics have been reported to cause hypoglycemia when
combined with sulfonylureas. This study investigated the impact of tolbutamide on the …

OBJECTIVE—The purpose of this study was to evaluate the efficacy and safety of vildagliptin
in elderly patients with type 2 diabetes. RESEARCH DESIGN AND METHODS—Efficacy …

Abstract Glucagon‐like peptide‐1 (7‐36) amide (GLP‐1) is a gut hormone, released
postprandially, which stimulates insulin secretion and insulin gene expression as well as …